TR2022007382A2 - EYE DROPS COMPOSITION CONTAINING NONSTEROIDAL ANTI-INFLAMMATORY ACTIVE SUBSTANCE - Google Patents
EYE DROPS COMPOSITION CONTAINING NONSTEROIDAL ANTI-INFLAMMATORY ACTIVE SUBSTANCEInfo
- Publication number
- TR2022007382A2 TR2022007382A2 TR2022/007382 TR2022007382A2 TR 2022007382 A2 TR2022007382 A2 TR 2022007382A2 TR 2022/007382 TR2022/007382 TR 2022/007382 TR 2022007382 A2 TR2022007382 A2 TR 2022007382A2
- Authority
- TR
- Turkey
- Prior art keywords
- sodium
- eye drop
- composition according
- pharmaceutically acceptable
- drop composition
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 63
- 239000003889 eye drop Substances 0.000 title claims abstract description 29
- 230000003110 anti-inflammatory effect Effects 0.000 title claims abstract description 17
- 239000013543 active substance Substances 0.000 title claims description 4
- 229940012356 eye drops Drugs 0.000 title description 3
- 239000004480 active ingredient Substances 0.000 claims abstract description 22
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 15
- 230000000699 topical effect Effects 0.000 claims abstract description 6
- QEFAQIPZVLVERP-UHFFFAOYSA-N nepafenac Chemical compound NC(=O)CC1=CC=CC(C(=O)C=2C=CC=CC=2)=C1N QEFAQIPZVLVERP-UHFFFAOYSA-N 0.000 claims description 18
- 229960001002 nepafenac Drugs 0.000 claims description 17
- 150000003839 salts Chemical class 0.000 claims description 17
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 12
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 claims description 10
- 229920000858 Cyclodextrin Polymers 0.000 claims description 9
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 9
- 239000003381 stabilizer Substances 0.000 claims description 9
- 239000006172 buffering agent Substances 0.000 claims description 8
- 239000003002 pH adjusting agent Substances 0.000 claims description 8
- 239000003755 preservative agent Substances 0.000 claims description 8
- 230000002335 preservative effect Effects 0.000 claims description 8
- 239000004034 viscosity adjusting agent Substances 0.000 claims description 8
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 6
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
- 229960000686 benzalkonium chloride Drugs 0.000 claims description 6
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims description 6
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 6
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 claims description 6
- 206010061218 Inflammation Diseases 0.000 claims description 5
- 229920002125 Sokalan® Polymers 0.000 claims description 5
- 235000010418 carrageenan Nutrition 0.000 claims description 5
- 239000000679 carrageenan Substances 0.000 claims description 5
- 229920001525 carrageenan Polymers 0.000 claims description 5
- 229940113118 carrageenan Drugs 0.000 claims description 5
- 229960004926 chlorobutanol Drugs 0.000 claims description 5
- 230000004054 inflammatory process Effects 0.000 claims description 5
- 229920002554 vinyl polymer Polymers 0.000 claims description 5
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims description 5
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 4
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 4
- 229960001631 carbomer Drugs 0.000 claims description 4
- 229960004106 citric acid Drugs 0.000 claims description 4
- 229910000397 disodium phosphate Inorganic materials 0.000 claims description 4
- 235000019800 disodium phosphate Nutrition 0.000 claims description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 4
- 239000001632 sodium acetate Substances 0.000 claims description 4
- 235000017281 sodium acetate Nutrition 0.000 claims description 4
- 235000010413 sodium alginate Nutrition 0.000 claims description 4
- 239000000661 sodium alginate Substances 0.000 claims description 4
- 229940005550 sodium alginate Drugs 0.000 claims description 4
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims description 3
- DSEKYWAQQVUQTP-XEWMWGOFSA-N (2r,4r,4as,6as,6as,6br,8ar,12ar,14as,14bs)-2-hydroxy-4,4a,6a,6b,8a,11,11,14a-octamethyl-2,4,5,6,6a,7,8,9,10,12,12a,13,14,14b-tetradecahydro-1h-picen-3-one Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)C(C)(C)CC[C@]1(C)CC[C@]2(C)[C@H]4CC[C@@]1(C)[C@H]3C[C@@H](O)C(=O)[C@@H]1C DSEKYWAQQVUQTP-XEWMWGOFSA-N 0.000 claims description 3
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 claims description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 3
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 claims description 3
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 claims description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 3
- 235000010323 ascorbic acid Nutrition 0.000 claims description 3
- 229960005070 ascorbic acid Drugs 0.000 claims description 3
- 239000011668 ascorbic acid Substances 0.000 claims description 3
- 239000000022 bacteriostatic agent Substances 0.000 claims description 3
- 239000000440 bentonite Substances 0.000 claims description 3
- 229910000278 bentonite Inorganic materials 0.000 claims description 3
- 235000012216 bentonite Nutrition 0.000 claims description 3
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 claims description 3
- 229960003655 bromfenac Drugs 0.000 claims description 3
- ZBPLOVFIXSTCRZ-UHFFFAOYSA-N bromfenac Chemical compound NC1=C(CC(O)=O)C=CC=C1C(=O)C1=CC=C(Br)C=C1 ZBPLOVFIXSTCRZ-UHFFFAOYSA-N 0.000 claims description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 3
- 229940105329 carboxymethylcellulose Drugs 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 229960002303 citric acid monohydrate Drugs 0.000 claims description 3
- 229960001259 diclofenac Drugs 0.000 claims description 3
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims description 3
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 claims description 3
- 229960000443 hydrochloric acid Drugs 0.000 claims description 3
- 239000007951 isotonicity adjuster Substances 0.000 claims description 3
- 229960004752 ketorolac Drugs 0.000 claims description 3
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 claims description 3
- 229920000609 methyl cellulose Polymers 0.000 claims description 3
- 239000001923 methylcellulose Substances 0.000 claims description 3
- 235000010981 methylcellulose Nutrition 0.000 claims description 3
- HWPKGOGLCKPRLZ-UHFFFAOYSA-M monosodium citrate Chemical compound [Na+].OC(=O)CC(O)(C([O-])=O)CC(O)=O HWPKGOGLCKPRLZ-UHFFFAOYSA-M 0.000 claims description 3
- 239000002524 monosodium citrate Substances 0.000 claims description 3
- 235000018342 monosodium citrate Nutrition 0.000 claims description 3
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims description 3
- 235000019799 monosodium phosphate Nutrition 0.000 claims description 3
- 229960003742 phenol Drugs 0.000 claims description 3
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 claims description 3
- 229940001607 sodium bisulfite Drugs 0.000 claims description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 3
- 229940001593 sodium carbonate Drugs 0.000 claims description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 3
- 235000002639 sodium chloride Nutrition 0.000 claims description 3
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims description 3
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 claims description 3
- CSMWJXBSXGUPGY-UHFFFAOYSA-L sodium dithionate Chemical compound [Na+].[Na+].[O-]S(=O)(=O)S([O-])(=O)=O CSMWJXBSXGUPGY-UHFFFAOYSA-L 0.000 claims description 3
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 claims description 3
- 229940083608 sodium hydroxide Drugs 0.000 claims description 3
- 229940001584 sodium metabisulfite Drugs 0.000 claims description 3
- 235000010262 sodium metabisulphite Nutrition 0.000 claims description 3
- 239000001488 sodium phosphate Substances 0.000 claims description 3
- 229910000162 sodium phosphate Inorganic materials 0.000 claims description 3
- 235000011008 sodium phosphates Nutrition 0.000 claims description 3
- 229940001482 sodium sulfite Drugs 0.000 claims description 3
- 235000010265 sodium sulphite Nutrition 0.000 claims description 3
- 230000003637 steroidlike Effects 0.000 claims description 3
- 239000004094 surface-active agent Substances 0.000 claims description 3
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 1
- 239000000243 solution Substances 0.000 description 16
- 239000002244 precipitate Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 4
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000002997 ophthalmic solution Substances 0.000 description 3
- 208000002177 Cataract Diseases 0.000 description 2
- -1 amide derivatives of 3-benzoylphenylacetic acid Chemical class 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 229940054534 ophthalmic solution Drugs 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 239000013049 sediment Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- OMDQUFIYNPYJFM-XKDAHURESA-N (2r,3r,4s,5r,6s)-2-(hydroxymethyl)-6-[[(2r,3s,4r,5s,6r)-4,5,6-trihydroxy-3-[(2s,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methoxy]oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@H](O)[C@H](O)O1 OMDQUFIYNPYJFM-XKDAHURESA-N 0.000 description 1
- 244000007835 Cyamopsis tetragonoloba Species 0.000 description 1
- 206010015946 Eye irritation Diseases 0.000 description 1
- 229920000926 Galactomannan Polymers 0.000 description 1
- 208000001344 Macular Edema Diseases 0.000 description 1
- 206010025415 Macular oedema Diseases 0.000 description 1
- NMLMACJWHPHKGR-NCOIDOBVSA-N P(1),P(4)-bis(uridin-5'-yl) tetraphosphate Chemical compound N1([C@@H]2O[C@@H]([C@H]([C@H]2O)O)COP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@H]([C@@H](O2)N2C(NC(=O)C=C2)=O)O)O)C=CC(=O)NC1=O NMLMACJWHPHKGR-NCOIDOBVSA-N 0.000 description 1
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 1
- 108050003243 Prostaglandin G/H synthase 1 Proteins 0.000 description 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 229950003529 diquafosol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 231100000013 eye irritation Toxicity 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 201000010230 macular retinal edema Diseases 0.000 description 1
- 229940012664 nevanac Drugs 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229940061102 topical suspension Drugs 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Abstract
Mevcut buluş, topikal olarak kullanılmak üzere en az bir nonsteroidal antienflamatuvar etken madde ve en az bir farmasötik olarak kabul edilebilir bir yardımcı madde ihtiva eden bir göz damlası bileşimi ile ilgilidir.The present invention relates to an eye drop composition for topical use containing at least one nonsteroidal anti-inflammatory active ingredient and at least one pharmaceutically acceptable excipient.
Description
Tarifname NONSTEROIDAL ANTIENFLAMATUVAR ETKEN MADDE IÇEREN GÖZ DAMLASI BILESIMI Bulusun Ilgili Oldugu Alan Mevcut bulus, topikal olarak kullanilmak üzere en az bir nonsteroidal antienflamatuvar etken madde ve en az bir farmasötik olarak kabul edilebilir yardimci madde ihtiva eden bir göz damlasi bilesimi ile ilgilidir. Daha özel olarak, söz konusu bilesim agri ve/veya iltihaplanma tedavisinde kullanilmak üzere sunulmaktadir. Teknigin Bilinen Durumu Nepafenak, genellikle reçeteli göz damlasi olarak %0.1'lik solüsyon (Nevanac®] veya %0.3'lük solüsyon (llevro®] olarak ticari adlari ile piyasada bulunabilen, nonsteroid antienflamatuvar bir ilaçtir (NSAID). Nepafenak etken maddesinin kimyasal yapisi asagida yer alan Formül l'de verilmektedir. Formül 1 Söz konusu ilaç, katarakt ameliyati ile iliskili olarak agri ve iltihabin tedavisinde kullanilmaktadir. Nepafenak ayrica, COX-1 ve COX-2 aktivitesinin bir inhibitörü olan amfenakin bir ön ilacidir. Avrupa Birligi'nde nepafenak, diyabetli kisilerde katarakt ameliyati ile iliskili postoperatif makula ödemi riskinin azaltilmasi için de endikedir. US 5475034 A sayili patent belgesinde, 3-benzoilfenilasetik asidin yeni ester ve amid türevleri açiklanmaktadir. Ayrica söz konusu belge kapsaminda açiklanan türevlerin, oftalmik enflamatuar bozukluklarin tedavisi için topikal olarak uygulanabilir bilesimlerde kullanimi da saglanmaktadir. EP 1819362 A2 sayili patent belgesi, nepafenak etken maddesinin topikal süspansiyon bilesimleri ile ilgilidir. Söz konusu bilesimler özellikle topikal oftalmik uygulamaya yöneliktir. EP 2586426 A1 sayili patent belgesi, bir karbomer olarak karboksivinil polimeri, bir guar olarak galaktomannayi ve bir borat bilesigi ihtiva eden süspansiyon bilesimlerine iliskindir. Teknigin bilinen durumunda yer alan nonsteroidal antienflamatuvar etken madde ihitva eden oftalmik çözeltilerinde yasanan en yaygin problem, söz konusu çözeltinin çökelti olusturmaksizinn saklanabilirlige, dayanikliliga ve stabiliteye sahip olmamasidir. Özellikle, ilacin muhafaza edilmesi sürecinde çözelti içerisinde birtakim çökeltiler meydana gelmekte ve bu çökeltiler sonrasinda uzaklastirilamamaktadir. Bilinen çözelti bilesimleri, bu sorununun üstesinden gelmeye yönelik tedbirler içerse de bilesimlerde yer alan yardimci maddelerle geçimsizlik sorunlari devam etmektedir. Ayrica isi, isik ve nem gibi dis faktörlere karsi yeterince dayaniklilik da saglanamamaktadir. Dolayisiyla teknikte çözelti içerisinde çökelti olusumunun engellendigi, stabilitesi, dayanikliligi ve çözünürlügü yüksek nonsteroidal antienflamatuvar etken madde ihtiva eden oftalmik çözelti bilesimlerine yönelik ihtiyaç devam etmektedir. Yukaridaki bilgiler isiginda görülmektedir ki, ilgili teknik alanda, diquafosol içeren bilesimlerin yüksek stabilitesinin ve dayanikliliginin saglandigi, agri ve /veya iltihaplanma tedavisinde endike ve bunlara ek olarak çözünürlügü yüksek oftalmik çözelti bilesimlerine yönelik bir ihtiyaç bulunmaktadir. Mevcut bulus kapsaminda bu amaçla, topikal olarak kullanilmak üzere en az bir nonsteroidal antienflamatuvar etken madde ve en az bir farmasötik olarak kabul edilebilir bir yardimci madde ihtiva eden bir göz damlasi bilesimi sunulmaktadir. Bulusun Kisa Açiklamasi Mevcut bulus bir yönüyle, topikal olarak kullanilmak üzere en az bir nonsteroidal antienflamatuvar etken madde ve en az bir farmasötik olarak kabul edilebilir yardimci madde ihtiva eden bir göz damlasi bilesimi sunmaktadir. Bahsedilen nonsteroidal etken madde, tercihen ketorolak veya bunun farmasötik olarak kabul edilebilir bir tuzunu, bromfenak veya bunun farmasötik kabul edilebilir bir tuzunu, nepafenak, diklofenak veya bunun farmasötik olarak kabul edilebilir bir tuzunu, flubiprofen veya bunun farmasötik olarak kabul edilebilir bir tuzunu içeren bir gruptan seçilebilir. Mevcut bulusa ait bilesim, nonsteroidal antienflamatuvar etken madde nepafenak veya bunun farmasötik olarak kabul edilebilir bir tuzudur. Mevcut bulusa ait bilesim, tercihen %0.01 ila %1 araliginda, daha tercihen %0.05 ila %1 araliginda nonsteroidal antienflamatuvar etken madde ihtiva edebilir. Daha da özel olarak söz konusu bilesim ayrica, %0.1 ila %1 araliginda nonsteroidal antienflamatuvar etken madde ihtiva edebilir. Mevcut bilesimin tercih edilen yapilanmalarinda yer alan farmasötik olarak kabul edilebilir yardimci madde tamponlayici ajan, izotonik ajan, bakteriyostatik madde, pH ayarlayici ajan, tonisite ayarlayici ajan, viskozite ayarlayici ajan, yüzey aktif madde, stabilizatör, koruyucu veya bunlarin kombinasyonlarini içeren bir gruptan seçilmektedir. Söz konusu bilesimde yer alan stabilizatör siklodekstrin, ceresin, karagenan, etilen glikol stearat, sodyum metabisülfat veya bunlarin kombinasyonlarini içeren bir gruptan seçilmektedir. Bahsedilen tamponlayici ajan sodyum fosfat, sodyum hidrojen fosfat, disodyum hidrojen fosfat, sodyum dihidrojen fosfat, sodyum asetat, monosodyum sitrat, sodyum klorür, sitrik asit monohidrat veya bunlarin kombinasyonlarini içeren bir gruptan seçilmektedir. Ayrica, bulusa ait koruyucu sodyum sülfit, sodyum bisülfit, sodyum metabisülfit, askorbik asit, fenol, benzil alkol, benzalkonyum klorür, klorobütanol veya bunlarin kombinasyonlarini içeren bir gruptan seçilmektedir. Söz konusu viskozite ayarlayici ajan ise, karbomer, bentonit, hidroksipropil metil selüloz, metil selüloz, karboksimetil selüloz, polivinil prolidon, sodyum karboksi metil selüloz veya bunlarin kombinasyonlarini içeren bir gruptan seçilmektedir. Bahsi geçen pH ayarlayici ajan, hidroklorik asit, sodyum hidroksit, sodyum karbonat, sitrik asit, sodyum aljinat veya bunlarin kombinasyonlarini içeren bir gruptan seçilmektedir. Mevcut bilesime ait pH degeri tercihen 4 ila 8 araliginda bir degere, özellikle tercihen 6,8 pH degerindedir. Bulusun bir baska yönü itibari ile, agri ve/veya iltihaplanma tedavisinde kullanilmak üzere mevcut bulusa göre sunulan bir göz damlasi bilesimi sunulmaktadir. Bulusun Ayrintili Açiklamasi Bu ayrintili açiklamada, mevcut bulusa göre olan topikal olarak kullanilmak üzere en az bir nonsteroidal antienflamatuvar etken madde ve en az bir farmasötik olarak kabul edilebilir yardimci madde ihtiva eden göz damlasi bilesimi konunun daha iyi anlasilmasi için açiklanmaktadir. Bahsedilen nonsteroidal etken madde, tercihen ketorolak veya farmasötik olarak kabul edilebilir bir tuzu, bromfenak veya farmasötik kabul edilebilir bir tuzu, nepafenak, diklofenak veya farmasötik olarak kabul edilebilir bir tuzu, flubiprofen veya farmasötik olarak kabul edilebilir bir tuzu arasindan seçilebilir. Mevcut bulusun tercih edilen yapilanmalarinda söz konusu bilesim nonsteroidal antienflamatuvar etken madde olarak nepafenak ihtiva edebilir. Bulusa ait oftalmik bilesim agirlikça %0.01 ila %1 (a/h] araliginda, tercihen %0.05 ila %1 (a/h] araliginda nepafenak ihtiva edebilir. Daha tercihen agirlikça %0.1 ila %1 (a/h] araliginda nepafenak ihtiva edebilir. Mevcut bulus sahipleri, ilgili etken maddenin bu agirlikça miktarda kullanilmasinin bulusa ait kullanima uygun göz damlasi bilesimi katarakt cerrahi ile iliskili olarak agri ve iltihaplanma tedavisinde daha etkili hale getirdigini görmüslerdir. Mevcut bulusa göre olan en az bir farmasötik olarak kabul edilebilir yardimci madde tamponlayici ajan, izotonik ajan, bakteriyostatik madde, pH ayarlayici ajan, tonisite ayarlayici ajan, viskozite ayarlayici ajan, yüzey aktif madde, stabilizatör, koruyucu veya bunlarin kombinasyonlarini içeren bir gruptan seçilebilir. Bulus kapsaminda farmasötik olarak kabul edilebilir yardimci maddeler ile tasarlanmis göz damlasi bilesimi problemlere bir çözüm sunularak ilgili teknik alanda yer alan bilesimlere kiyasla daha yüksek çözünürlüge, kararliliga ve dayanikliliga sahip bir göz damlasi bilesimi saglanmaktadir. Mevcut bulusa göre olan en az bir farmasötik olarak kabul edilebilir yardimci madde tercihen en az bir stabilizatör ihtiva etmektedir. Söz konusu stabilizatör siklodekstrin, ceresin, karagenan, etilen glikol stearat, sodyum metabisülfat veya bunlarin kombinasyonlarini içeren bir gruptan seçilmektedir. Mevcut bulusun tercih edilen yapilanmalarinda söz konusu bilesim en az bir etken madde, siklodekstrin ve diger yardimci maddeleri ihtiva edebilir. Mevcut bulusun tercih edilen yapilanmalarinda söz konusu bilesimin siklodekstrin ile bir arada kullanilmasi ile mevcut bulusa ait bilesimin homojenligi, stabilitesi, ilaç emilimi artmakta ve dolayisiyla bahsedilen bilesimin gözde yol açabilecegi tahrisi en aza indirmektedir. Ayrica, mevcut bulus sahipleri, yukarida bahsedilen siklodekstrin katki maddesinin nepafenak etken maddesi ile bir araya getirilmesiyle beraber göz damlasi solüsyonunun saklanmasi sürecinde meydana gelen çözelti içerisindeki çökelti olusumunu sürpriz bir sekilde engelleyebildigini kesfetmislerdir. Böylelikle, tamponlayici ajan, viskozite ayarlayici ajan, pH ayarlayici ajan, stabilizatör ve/veya koruyucunun bir arada kullanildigi yapilanmalarda söz konusu göz damlasi bilesiminin sebep oldugu göz irritasyonunun sasirtici bir sekilde azaldigi ve ayrica çözeltinin muhafaza sürecinin de güçlendirildigi ortaya koyulmaktadir. Ayrica, söz konusu koruyucu da sodyum sülfit, sodyum bisülfit, sodyum metabisülfit, askorbik asit, fenol, benzil alkol, benzalkonyum klorür, klorobütanol veya bunlarin kombinasyonlarini içeren bir gruptan seçilmektedir. Bahsi geçen tamponlayici ajan sodyum fosfat, sodyum hidrojen fosfat, disodyum hidrojen fosfat, sodyum dihidrojen fosfat, sodyum asetat, monosodyum sitrat, sodyum klorür, sitrik asit monohidrat veya bunlarin kombinasyonlarini içeren bir gruptan seçilmektedir. Söz konusu viskozite ayarlayici ajan karbomer, bentonit, hidroksipropil metil selüloz, metil selüloz, karboksimetil selüloz, polivinil prolidon, sodyum karboksi metil selüloz veya bunlarin kombinasyonlarini içeren bir gruptan seçilmektedir. Bahsedilen pH ayarlayici ajan ise, hidroklorik asit, sodyum hidroksit, sodyum karbonat, sitrik asit, sodyum aljinat veya bunlarin kombinasyonlarini içeren bir gruptan seçilmektedir. Mevcut bulusa ait çözeltinin pH degeri 4 ila 8 araliginda bir degere, daha tercihen 6,8 pH degerine ayarlanmaktadir. Mevcut bulusun ileri yapilanmalari, yukarida bahsedilenlerin haricinde bulusa göre sunulan kullanima uygun farmasötik olarak kabul edilebilir eksipiyanlar, çözücüler, baglayicilar, yaglayicilar, kaydiricilar, dolgu maddeleri, selatlayici ajan, islatma maddelerini de içerebilir. Söz konusu yardimci maddelerin yukarida bahsedilmeyen kombinasyonlari da mevcut bulusun kapsami disinda birakilmamalidir. Dolayisiyla, mevcut bulus çözelti içerisinde çökelti olusumunu engelleyerek daha iyi bir dayanikliliga ve kararliliga sahip bir göz damlasi bilesimi sunmasi sebebiyle avantajlidir ve bu yönüyle teknikte bir ilerleme saglamaktadir. Mevcut bulusa ait bilesimin teknik etkisinin dayanikliliga fayda sagladigi ve bu sebeple mevcut bilesimlere kiyasla daha avantajli oldugu ortaya koyulmaktadir. ÖRNEKLER Tercih edilen yapilanmalarda, mevcut bulusa ait göz damlasi bilesimi asagidaki bilesenleri ihtiva etmektedir: Bilesen Agirlikça (%) (a/h) Nepafenak veya bunun tuzu 0,1 - 10 Tamponlayici ajan 0,1 - 10 Viskozite ayarlayici ajan 0,1 - 10 pH ayarlayici ajan 0,1 - 10 Stabilizatör 0,1 - 10 Koruyucu madde 0,001 - 0,1 Bilesen Agirlik (g) Nepafenak 0.300 Sodyum hidrojen fosfat 0.200 Hidroksipropil metil selüloz 0.420 Sodyum hidroksit 0-170 Siklodekstrin 0-100 Benzalkonyum klorür 0.003 Saf su Yeterli miktarda hidroksit, 0.10 g siklodekstrin ve 0.003 benzalkonyum klorür, saf su içerisinde çözünmesi saglanmistir. Böylece elde edilen çözeltinin hacmi 3 mL olmustur. Bilesen Agirlik (g) Nepafenak 0.100 PoliVinil prolidon 0.320 Sitrik asit 0.120 Karagenan 0.110 Klorobütanol 0.002 Saf su Yeterli miktarda g karagenan ve 0.002 klorobütanol, saf su içerisinde çözünmesi saglanmistir. Böylece elde edilen çözeltinin hacmi 3 mL olmustur. Bilesen Agirlik (g) Nepafenak 0.200 Sodyum asetat 0.200 PoliVinil prolidon 0.320 Sodyum aljinat 0.240 Siklodekstrin 0.200 Benzalkonyum klorür 0.002 Saf su Yeterli miktarda siklodekstrinve 0.002 benzetonyum klorür, saf su içerisinde çözünmesi saglanmistir. Böylece elde edilen çözeltinin hacmi 3 mL olmustur. Yukarida tarif edilen örnek bilesimlerin her biri, bir cam kap içerisinde 25°C'de üç ay boyunca saklanmis ve ardindan söz konusu bilesimlerin görünüslerinde herhangi bir degisiklik olmadigi saptanmistir. Ayrica, bu süreçlerdeki çökelti içerisinde meydana gelen çökeltilerin miktarinin azaldigi da ortaya koyulmustur. Mevcut bulus, nepafenak etken maddesinin veya bunun tuzunun farmasötik olarak kabul edilebilir yardimci maddeler ile bir araya getirilerek saglanan spesifik bilesimi ile çözelti içerisinde çökelti olusumunun engellenmesi saglanarak iyi bir dayanikliliga ve kararliliga sahip ve ayrica isi, isik ve nem gibi dis faktörlere karsi yeterince dayaniklilik gösteren göz damlasi bilesimleri saglamasi bakimindan avantajlidir. Bulusun koruma kapsami ekte verilen istemlerde belirtilmis olup teknikte uzman bir kisinin, bulusun ana temasindan ayrilmadan yukarida anlatilanlar isiginda benzer yapilanmalar ortaya koyabilecegi açiktir. TR Description EYE DROPS COMPOSITION CONTAINING NONSTEROIDAL ANTI-INFLAMMATORY ACTIVE INGREDIENT Field of the Invention The present invention relates to an eye drop composition containing at least one non-steroidal anti-inflammatory active ingredient and at least one pharmaceutically acceptable excipient to be used topically. More specifically, the composition is provided for use in the treatment of pain and/or inflammation. State of the Art Nepafenac is a nonsteroidal anti-inflammatory drug (NSAID) that is generally available as prescription eye drops under the trade names of 0.1% solution (Nevanac®] or 0.3% solution (llevro®].The chemical structure of the active ingredient Nepafenac is as follows. Formula 1 Nepafenac is also used in the European Union as a prodrug of amfenacine, an inhibitor of COX-1 and COX-2 activity. It is also indicated for reducing the risk of postoperative macular edema associated with cataract surgery in people with diabetes. US Patent No. 5475034 A discloses novel ester and amide derivatives of 3-benzoylphenylacetic acid. Additionally, the derivatives disclosed therein are used in topically applicable compositions for the treatment of ophthalmic inflammatory disorders. The patent document numbered EP 1819362 A2 is related to topical suspension compositions of the active ingredient nepafenac. The compositions are particularly suitable for topical ophthalmic application. Patent document EP 2586426 A1 relates to suspension compositions containing carboxyvinyl polymer as a carbomer, galactomannan as a guar and a borate compound. The most common problem encountered in ophthalmic solutions containing nonsteroidal anti-inflammatory active substances in the state of the art is that the solution in question does not have the ability to be stored without forming a precipitate, durability and stability. In particular, during the preservation of the drug, some precipitates form in the solution and these precipitates cannot be removed afterwards. Although known solution compositions contain measures to overcome this problem, incompatibility problems with the auxiliary substances in the compositions continue. In addition, sufficient resistance against external factors such as heat, light and humidity cannot be provided. Therefore, there is still a need in the art for ophthalmic solution compositions containing nonsteroidal anti-inflammatory active substances that prevent the formation of precipitates in the solution and have high stability, durability and solubility. In the light of the above information, it can be seen that there is a need in the relevant technical field for ophthalmic solution compositions with high solubility, which are indicated in the treatment of pain and/or inflammation, where the high stability and durability of diquafosol-containing compositions are ensured. For this purpose, within the scope of the present invention, an eye drop composition containing at least one nonsteroidal anti-inflammatory active ingredient and at least one pharmaceutically acceptable excipient for topical use is provided. Brief Description of the Invention In one aspect, the present invention provides an eye drop composition for topical use comprising at least one nonsteroidal anti-inflammatory active ingredient and at least one pharmaceutically acceptable excipient. Said nonsteroidal active ingredient may preferably be selected from the group consisting of ketorolac or a pharmaceutically acceptable salt thereof, bromfenac or a pharmaceutically acceptable salt thereof, nepafenac, diclofenac or a pharmaceutically acceptable salt thereof, flubiprofen or a pharmaceutically acceptable salt thereof. . The composition of the present invention is the nonsteroidal anti-inflammatory active ingredient nepafenac or a pharmaceutically acceptable salt thereof. The composition of the present invention may preferably contain 0.01% to 1%, more preferably 0.05% to 1% nonsteroidal anti-inflammatory active ingredient. More specifically, the composition may further contain from 0.1% to 1% nonsteroidal anti-inflammatory active ingredient. The pharmaceutically acceptable excipient in preferred embodiments of the present composition is selected from the group consisting of buffering agent, isotonic agent, bacteriostatic agent, pH adjusting agent, tonicity adjusting agent, viscosity adjusting agent, surfactant, stabilizer, preservative, or combinations thereof. The stabilizer contained in the composition in question is selected from a group including cyclodextrin, ceresin, carrageenan, ethylene glycol stearate, sodium metabisulfate or combinations thereof. Said buffering agent is selected from the group consisting of sodium phosphate, sodium hydrogen phosphate, disodium hydrogen phosphate, sodium dihydrogen phosphate, sodium acetate, monosodium citrate, sodium chloride, citric acid monohydrate or combinations thereof. Furthermore, the preservative of the invention is selected from the group consisting of sodium sulfite, sodium bisulfite, sodium metabisulfite, ascorbic acid, phenol, benzyl alcohol, benzalkonium chloride, chlorobutanol, or combinations thereof. The viscosity adjusting agent in question is selected from a group including carbomer, bentonite, hydroxypropyl methyl cellulose, methyl cellulose, carboxymethyl cellulose, polyvinyl prolidone, sodium carboxy methyl cellulose or combinations thereof. Said pH adjusting agent is selected from the group consisting of hydrochloric acid, sodium hydroxide, sodium carbonate, citric acid, sodium alginate or combinations thereof. The pH value of the present composition is preferably in the range of 4 to 8, particularly preferably pH 6.8. In another aspect of the invention, there is provided an eye drop composition according to the present invention for use in the treatment of pain and/or inflammation. Detailed Description of the Invention In this detailed description, the eye drop composition containing at least one nonsteroidal anti-inflammatory active ingredient and at least one pharmaceutically acceptable excipient for topical use according to the present invention is described for a better understanding of the subject. Said nonsteroidal active ingredient may preferably be selected from ketorolac or a pharmaceutically acceptable salt thereof, bromfenac or a pharmaceutically acceptable salt thereof, nepafenac, diclofenac or a pharmaceutically acceptable salt thereof, flubiprofen or a pharmaceutically acceptable salt thereof. In preferred embodiments of the present invention, the composition may contain nepafenac as a nonsteroidal anti-inflammatory active ingredient. The ophthalmic composition of the invention may contain nepafenac in the range of 0.01% to 1% (w/v), preferably 0.05% to 1% (w/v), more preferably 0.1% to 1% (w/v). The present inventors have found that the use of this weight amount of the active ingredient makes the inventive eye drop composition more effective in treating pain and inflammation associated with cataract surgery, at least one pharmaceutically acceptable excipient buffering agent according to the present invention. The eye drop composition designed with pharmaceutically acceptable excipients within the scope of the invention can be selected from a group including isotonic agent, bacteriostatic agent, pH adjusting agent, tonicity adjusting agent, viscosity adjusting agent, surfactant, stabilizer, preservative or combinations thereof, providing a solution to the problems. An eye drop composition with higher solubility, stability and durability compared to compositions in the relevant art is provided. At least one pharmaceutically acceptable excipient according to the present invention preferably contains at least one stabilizer. The stabilizer is selected from the group consisting of cyclodextrin, ceresin, carrageenan, ethylene glycol stearate, sodium metabisulfate or combinations thereof. In preferred embodiments of the present invention, the composition in question may contain at least one active ingredient, cyclodextrin and other excipients. By using the composition in question together with cyclodextrin in preferred embodiments of the present invention, the homogeneity, stability and drug absorption of the composition of the present invention increases and therefore minimizes the irritation that the said composition may cause in the eyes. Moreover, the present inventors have discovered that the above-mentioned cyclodextrin additive, combined with the active ingredient nepafenac, can surprisingly prevent the formation of precipitates in the solution that occurs during the storage of eye drop solution. Thus, it is revealed that in embodiments where buffering agent, viscosity adjusting agent, pH adjusting agent, stabilizer and/or preservative are used together, the eye irritation caused by the eye drop composition in question is surprisingly reduced and the preservation process of the solution is also strengthened. Additionally, said preservative is selected from the group consisting of sodium sulfite, sodium bisulfite, sodium metabisulfite, ascorbic acid, phenol, benzyl alcohol, benzalkonium chloride, chlorobutanol, or combinations thereof. Said buffering agent is selected from the group consisting of sodium phosphate, sodium hydrogen phosphate, disodium hydrogen phosphate, sodium dihydrogen phosphate, sodium acetate, monosodium citrate, sodium chloride, citric acid monohydrate or combinations thereof. The viscosity adjusting agent in question is selected from the group consisting of carbomer, bentonite, hydroxypropyl methyl cellulose, methyl cellulose, carboxymethyl cellulose, polyvinyl prolidone, sodium carboxy methyl cellulose, or combinations thereof. Said pH adjusting agent is selected from a group including hydrochloric acid, sodium hydroxide, sodium carbonate, citric acid, sodium alginate or combinations thereof. The pH value of the solution of the present invention is adjusted to a value in the range of 4 to 8, more preferably to a pH value of 6.8. Further embodiments of the present invention may include, in addition to those mentioned above, pharmaceutically acceptable excipients, solvents, binders, lubricants, lubricants, fillers, chelating agents, wetting agents suitable for use according to the invention. Combinations of these excipients not mentioned above should not be excluded from the scope of the present invention. Therefore, the present invention is advantageous as it provides an eye drop composition with better durability and stability by preventing precipitate formation in solution, and in this respect it provides an advance in the technique. It is revealed that the technical effect of the composition of the present invention benefits durability and is therefore more advantageous compared to existing compositions. EXAMPLES In preferred embodiments, the eye drop composition of the present invention contains the following ingredients: Component By Weight (%) (w/v) Nepafenac or salt thereof 0.1 - 10 Buffering agent 0.1 - 10 Viscosity adjusting agent 0.1 - 10 pH adjusting agent 0.1 - 10 Stabilizer 0.1 - 10 Preservative 0.001 - 0.1 Component Weight (g) Nepafenac 0.300 Sodium hydrogen phosphate 0.200 Hydroxypropyl methyl cellulose 0.420 Sodium hydroxide 0-170 Cyclodextrin 0-100 Benzalkonium chloride 0.003 Pure water A sufficient amount of hydroxide, 0.10 g cyclodextrin and 0.003 benzalkonium chloride was dissolved in pure water. Thus, the volume of the solution obtained was 3 mL. Component Weight (g) Nepafenac 0.100 PolyVinyl prolidone 0.320 Citric acid 0.120 Carrageenan 0.110 Chlorobutanol 0.002 Pure water A sufficient amount of g carrageenan and 0.002 chlorobutanol was dissolved in pure water. Thus, the volume of the solution obtained was 3 mL. Component Weight (g) Nepafenac 0.200 Sodium acetate 0.200 PolyVinyl prolidone 0.320 Sodium alginate 0.240 Cyclodextrin 0.200 Benzalkonium chloride 0.002 Pure water A sufficient amount of cyclodextrin and 0.002 benzethonium chloride were dissolved in pure water. Thus, the volume of the solution obtained was 3 mL. Each of the exemplary compositions described above were stored in a glass container at 25°C for three months and thereafter it was determined that there was no change in the appearance of the compositions. It has also been revealed that the amount of sediments formed in the sediment in these processes decreases. The present invention provides eye protection that has good durability and stability and is also sufficiently resistant to external factors such as heat, light and moisture by preventing the formation of precipitates in solution with the specific composition of the active ingredient nepafenac or its salt combined with pharmaceutically acceptable excipients. It is advantageous in terms of providing droplet compositions. The protection scope of the invention is specified in the attached claims, and it is clear that a person skilled in the art can produce similar structures in the light of what is explained above, without departing from the main theme of the invention. TR
Claims (1)
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TR2022007382A2 true TR2022007382A2 (en) | 2023-11-21 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU761040B2 (en) | Aqueous liquid preparations | |
| US5110493A (en) | Ophthalmic NSAID formulations containing a quaternary ammonium preservative and a nonionic surfactant | |
| JP4933897B2 (en) | Intraocular transfer-promoting aqueous eye drops | |
| EP2002841A1 (en) | Ophthalmic composition comprising xanthan gum and glucose | |
| JPH02264716A (en) | Tranilast aqueous solution preparation | |
| JPS62178514A (en) | Agent for lowering intraocular pressure | |
| AU2012283895A1 (en) | Fixed dose combination of bimatoprost and brimonidine | |
| KR20010012521A (en) | Antiseptic composition | |
| US9889088B2 (en) | Alpha-2 adrenergic agonist having long duration of intraocular pressure-lowering effect | |
| WO1996008244A1 (en) | Eye drops for repairing corneal disturbance | |
| CN101977630B (en) | Ophthalmic composition | |
| WO2016072440A1 (en) | Ophthalmic aqueous composition | |
| CA2824433C (en) | Aqueous liquid bromfenac composition having preservative efficacy | |
| JPH115744A (en) | Aqueous solution preparation for external use containing hyaluronic acid | |
| JPH03118321A (en) | Transparent and stable chromolyn agent | |
| TR2022007382A2 (en) | EYE DROPS COMPOSITION CONTAINING NONSTEROIDAL ANTI-INFLAMMATORY ACTIVE SUBSTANCE | |
| US20080039423A1 (en) | Ophthalmic Composition Containing Xanthan Gum and Amino Acid | |
| JP4442118B2 (en) | Stable eye drops | |
| JPH1029937A (en) | Pharmaceutical preparation of mefenamic acid aqueous solution | |
| JP4541504B2 (en) | A stable aqueous solution formulation containing tranilast or a pharmacologically acceptable salt thereof as an active ingredient | |
| TR2022007363A2 (en) | COMPOSITION CONTAINING NONSTEROIDAL ANTI-INFLAMMATORY ACTIVE INGREDIENT | |
| JP4779382B2 (en) | Composition for eye drops | |
| US20140275197A1 (en) | Alpha-2 adrenergic agonist for treating intraocular pressure and ocular diseases through intravitreal and intracameral routes | |
| JP2005008625A (en) | Eye lotion containing quinolone-based antibacterial compound | |
| JP2005247795A (en) | Stable eye drops |